Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Life-threatening hyponatraemia and intramuscular olanzapine: the world’s longest therapeutic trial
  1. Jaspreet Phull1,
  2. Steffan Davies2
  1. 1Low Secure and Community Forensic Directorate, Nottinghamshire Healthcare NHS Trust, Nottingham, UK
  2. 2MDO Services, Northamptonshire Healthcare NHS Foundation Trust, Northampton, UK
  1. Correspondence to Dr Jaspreet Phull, jsphull{at}yahoo.com

Summary

This case report provides a different perspective on the management of a patient with a psychotic illness. The detained patient, a man aged 50, had specific delusional beliefs about toxins affecting his kidneys, such that he needed to drink water to ‘detoxify’ himself. This resulted in him developing life-threatening hyponatraemia. It became clear that he was very resistant to taking oral medication and was reluctant to engage with any psychological treatment. A novel approach was considered, involving the ‘off licence’ use of short acting intramuscular olanzapine for the successful treatment of the psychotic illness. The case demonstrates the safe use of intramuscular olanzapine for 155 days, which is the longest reported case for the use of intramuscular olanzapine for the treatment of a psychotic illness. The individual was later discharged on oral olanzapine.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.